



Respiratory tract defense mechanisms **Ciliary structure and function** Upper airway Lower Airway 9 + 2 microtubule structure ٠ Mechanical barriers • Nasal turbinates • Glottis Branching airways Mucociliary escalator Alveolar space defenses Major proteins: tubulin and dynein Ciliary beat frequency 12-15 Hz • Reflexes Alveolar lining fluid · Cough, sneeze · Free fatty acids Maintenance of oropharyngeal flora • Saliva • Bacterial competition Lysozyme Iron-binding proteins IgG Surfactant Cellular components Naturally occurring bacterial binding site analogues Macrophages Polymorphonuclear cells Lymphocytes Local immunoglobulins

Mechanical lung host defenses

- The nose and mucociliary transport systems comprise the main mechanical defense system of the lungs
- Particles greater than 10 microns settle in the upper airways and rarely enter the lower airways
- Particles between 5-10 microns deposit in the trachea and main bronchi and can be removed by mucociliary transport





Diseases associated with abnormal ciliary function

- Primary ciliary dyskinesia; immotile cilia syndrome; Kartagener's syndrome; autosomal recessive
- Young's syndrome: sinusitis, bronchiectasis, obstructive azospermia; ? location of defect
- Cystic fibrosis; autosomal recessive
- **Chronic bronchitis**



Tobacco smoke and ciliary structure and function

- Smokers and ex-smokers have a higher level of ciliary structural abnormalities (17% of cilia) than never smokers (0.7%)
- Verra F et al. Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers. Am J Respir Crit Care Med 1995;151:630-4
- Ciliary beat frequency is not diminished by age, but is decreased similarly in smokers and those exposed to environmental tobacco smoke Agius et al. Age, smoking and nasal ciliary beat frequency. Clin Otolaryngol 1998; 23: 227-30

Stimulators and inhibitors of ciliary function

- Increase ciliary beat frequency
 - beta-adrenergic agonists (via adenylate cyclase, cAMP, and protein kinase A pathways
 - Anticholinergic agents (via protein kinase C pathways)
 - Increase in intracellular Na+/CI- ratio
- Decrease ciliary beat frequency
- Neuropeptide Y, major basic protien
- Bacterial products (pyocyanin, 1-_ hydroxyphenazine, and others)



SEM of terminal bronchioles and alveolar ducts

Humoral immune functions of the lung

- Lymphocytes in the lung are found in submucosal collections known as bronchial associated lymphoid tissue (BALT); Ig may also diffuse into the lung
- IgG, IgA, and IgE are all present in measurable amounts in the lung
- IgA, IgG₃ and IgG₄ are present in greater concentration in the lung than in serum
- IgG and IgA contribute significantly to defense
 against infection in the lung

Humoral immunodeficiency syndromes and the lung

Syndrome	Abnormality	Age of onset	Organisms Causing infection
IgA deficiency	lgA < 5 mg/dl	adulthood	similar to CVID but much less severe
IgG subclass deficiency	most severe clinically with lgG ₁ , lgG ₃	adulthood	similar to CVID

anu		,					
	Albumin	IgG1	lgG2	lgG3	IgG4	IgA	IgE
Serum*	49	4.5	2.1	0.03	0.09	1.98	199
BAL**	655	50	22	1.4	4.0	183	9.1
ratio [BAL/seru	ım]	0.88	0.95	4.2	5	7.9	3.8



Syndrome	Abnormality	Age of onset	Organisms Causing infection
Bruton's X-linked Agamma- globulinemia	lgG < 200mg/dl IgA, IgM, IgE, IgD absent	infancy	S. pneumoniae H. influenzae S. aureus
Common Variable Immune Deficiency	IgG<300mg/dl IgA, IgM Iow; antibody responses to vaccines	adulthood	same as above



Cellular immune defenses of the lung

- · Alveolar macrophages: 95% of cells recovered by BAL
- · Dendritic cells: 0.5% of cells recovered by BAL
- Lymphocytes: 1-2 % of cells recovered by BAL - CD4+ T cells
 - CD8+ T cells
- Neutrophils: not present in healthy lungs; recruited to the lung by a variety of stimuli

Receptors expressed and ligands recognized by alveolar macrophages

- Immunoglobulins (Fc receptors) - IgG₁, IgG₃, IgE, IgA
- Protein, cytokine, and matrix receptors Fibronectin, fibrin, lactoferrin, transferrin, GM-CSF, IFN-7, IL-2, IL-4, IL-1, IL-1RA
- Adhesion molecules and other receptors
 - MHC-II, CD4, CD1, CD18 (β-integrin), CD29 β-integrin), ICAM-1, CD14 (LPS)
- **Complement receptors** C3b, C4b, C3d, C5a
- Lectin receptors alpha-linked galactose receptors. N
 - acetylgalactosamine residues, a-linked fructose residues, mannose residues

Alveolar macrophages

- · The resident immune cell of the alveolar space
- Derived from bone marrow precursors, by way of the blood monocyte
- Proliferation may occur in the interstitium and alveolar space
- Key roles: phagocytosis and immune interactions



Cytokines and other bioactive substances released from alveolar macrophages

Arachidonate metabolites

- Thromboxane A2 PGE₂, D₂, F₂
- LTB4
- 5-HETE
- · Cytokines/chemokines
 - IL-1, IL-1RA - IL-6
 - TNF-α
 - IFN-α/β
- Nitric oxide Constituitive Inducible? Enzymes

 $- 0_2^{-} - H_2^{-} O_2^{-}$

- Metalloproteinases
- Elastase
- Procoagulant activity

Reactive oxygen species

Hydroxyl radical



Infectious pulmonary complications of **HIV infection**

- CD4+ T-cell count CD4+ T-cell count >250/mm³ <250/mm³ Pneumocystis carinii
- Bacterial pneumonia Reactivation tuberculosis
 - - Primary tuberculosis - Fungal infections:
 - Cryptococcus

pneumonia

- Geographic fungus
- Aspergillus spp.
- CMV pneumonitis

Lung-specific host responses in pulmonary tuberculosis

Hypothesis: clinical manifestations of tuberculosis are affected by the local immune response elicited by *M. tuberculosis*

Study design:

- BAL performed on patients with active, untreated, pulmonary tuberculosis
- cells and BALF obtained from one radiographically involved and one uninvolved lung segment
- cell count and differential performed on samples

Local cellular immune

responses in patients with

– aliquot of cells (10⁶/ml) cultured for 24 hr in serum-free RPMI and supernatants assayed for TNF- α , IL1- β , IFN- γ , TGF-β

AJRCCM 1998: 157: 729-735

Understanding the human host response to tuberculosis

- · Development of adjunctive immunotherapy for tuberculosis:
 - Treatment of drug resistant organisms
 - Shorten duration of treatment for drug susceptible disease
- Identify correlates of immunity to M. tuberculosis infection and disease
 - Predict success of candidate vaccines
- · Identify new diagnostic approaches

pulmonary	tuberc	ulosi	5		
BAL cells	no. of pts	<u>s. HIV +</u>	smear +	cavitary CXR	
>80% macrophag	es ¹⁰	6	6	2	
>20% lymphocyte	s ⁸	2	0	0	
>20% PMN	13	2	12	7	
			AJ	RCCM 1998; 157: 729	-735





Interferon-γ as adjunctive immunotherapy for MDR-TB

- Hypothesis: interferon-y may aid outcome in MDR-TB by improving host defenses against *M. tuberculosis*
- Study design:
 - patients: smear positive MDR-TB despite documented compliance with best possible medical regimen
 - adminstration of IFN-g: drug given as 500 mg dose via aerosol nebulizer t.i.w. for 4 weeks
 - data collection: weekly vital signs, symptoms, sputum smears and cultures; HRCT and BAL at beginning and end of treatment

Lancet 1997; 349: 1513-1515



Patient / Drug rx		Duration of drug rx	AFB Smear Pre-rx	results Post-rx
1	cipro, capreo, clofazamine, rifabutin	24 months	++	-
2	INH, oflox, cyclo, ethionamide	12 months	++	-
3	capreo, cipro, PZA, cyclo, ethionamide	13 months	++++	-
4	ethambutol, PAS, oflox, ethionamide, capreo	10 months	+	-
5	PAS, cyclo, amikacin, ethionamide, clofazamine	5 months	+++	-







































